Literature DB >> 27538188

Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial.

Sandra D Isidean1, Marie-Hélène Mayrand1,2, Agnihotram V Ramanakumar1, Laura Gilbert3, Stephanie L Reid3, Isabel Rodrigues4, Alex Ferenczy5, Sam Ratnam6, François Coutlée1,7, Eduardo L Franco8.   

Abstract

The Canadian Cervical Cancer Screening Trial was a randomized controlled trial comparing the performance of human papillomavirus (HPV) testing and Papanicolaou cytology to detect cervical intraepithelial neoplasia of grades 2 or worse (CIN2+) among women aged 30-69 years attending routine cervical cancer screening in Montreal and St. John's, Canada (n = 10,154). We examined screening and prognostic values of enrollment cytologic and HPV testing results. Extended follow-up data were available for St. John's participants (n = 5,754; 501,682.6 person-months). HPV testing detected more CIN2+ than cytology during protocol-defined (82.9 vs. 44.4%) and extended (54.2 vs. 19.3%) follow-up periods, respectively. Three-year risks ranged from 0.87% (95% CI: 0.37-2.05) for HPV-/Pap- women to 35.77% (95% CI: 25.88-48.04) for HPV+/Pap+ women. Genotype-specific risks ranged from 0.90% (95% CI: 0.40-2.01) to 43.84% (95% CI: 32.42-57.24) among HPV- and HPV16+ women, respectively, exceeding those associated with Pap+ or HPV+ results taken individually or jointly. Ten-year risks ranged from 1.15% (95% CI: 0.60-2.19) for HPV-/Pap- women to 26.05% (95% CI: 15.34-42.13) for HPV+/Pap+ women and genotype-specific risks ranged from 1.13% (95% CI: 0.59-2.14) to 32.78% (95% CI: 21.15-48.51) among women testing HPV- and HPV16+, respectively. Abnormal cytology stratified risks most meaningfully for HPV+ women. Primary HPV testing every 3 years provided a similar or greater level of reassurance against disease risks as currently recommended screening strategies. HPV-based cervical screening may allow for greater disease detection than cytology-based screening and permit safe extensions of screening intervals; genotype-specific testing could provide further improvement in the positive predictive value of such screening.
© 2016 UICC.

Entities:  

Keywords:  cervical cancer; cytology; genotyping; human papillomavirus; screening

Mesh:

Year:  2016        PMID: 27538188     DOI: 10.1002/ijc.30385

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Self-sampling for cervical cancer screening: Empowering women to lead a paradigm change in cancer control.

Authors:  E L Franco
Journal:  Curr Oncol       Date:  2018-02-28       Impact factor: 3.677

2.  HPV self-sampling: A promising approach to reduce cervical cancer screening disparities in Canada.

Authors:  M Vahabi; A Lofters
Journal:  Curr Oncol       Date:  2018-02-28       Impact factor: 3.677

3.  Ensuring a Successful Transition From Cytology to Human Papillomavirus-Based Primary Cervical Cancer Screening in Canada by Investigating the Psychosocial Correlates of Women's Intentions: Protocol for an Observational Study.

Authors:  Gabrielle Griffin-Mathieu; Ben Haward; Ovidiu Tatar; Patricia Zhu; Samara Perez; Gilla K Shapiro; Emily McBride; Erika L Thompson; Laurie W Smith; Aisha K Lofters; Ellen M Daley; Juliet R Guichon; Jo Waller; Marc Steben; Kathleen M Decker; Marie-Helene Mayrand; Julia M L Brotherton; Gina S Ogilvie; Gregory D Zimet; Teresa Norris; Zeev Rosberger
Journal:  JMIR Res Protoc       Date:  2022-06-16

4.  Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort.

Authors:  Anna Gottschlich; Dirk van Niekerk; Laurie W Smith; Lovedeep Gondara; Joy Melnikow; Darrel A Cook; Marette Lee; Gavin Stuart; Ruth E Martin; Stuart Peacock; Eduardo L Franco; Andrew Coldman; Mel Krajden; Gina Ogilvie
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-20       Impact factor: 4.254

5.  Primary HPV testing recommendations of US providers, 2015.

Authors:  Crystale Purvis Cooper; Mona Saraiya
Journal:  Prev Med       Date:  2017-12       Impact factor: 4.018

6.  PCR-RFLP assay as an option for primary HPV test.

Authors:  L Golfetto; E V Alves; T R Martins; T C M Sincero; J B S Castro; C Dannebrock; J G Oliveira; J E Levi; A S C Onofre; M L Bazzo
Journal:  Braz J Med Biol Res       Date:  2018-03-26       Impact factor: 2.590

7.  Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.

Authors:  Karen Canfell; Michael Caruana; Val Gebski; Jessica Darlington-Brown; Stella Heley; Julia Brotherton; Dorota Gertig; Chloe J Jennett; Annabelle Farnsworth; Jeffrey Tan; C David Wrede; Philip E Castle; Marion Saville
Journal:  PLoS Med       Date:  2017-09-19       Impact factor: 11.069

8.  Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany.

Authors:  Johannes Horn; Agnieszka Denecke; Alexander Luyten; Beate Rothe; Axel Reinecke-Lüthge; Rafael Mikolajczyk; Karl Ulrich Petry
Journal:  Br J Cancer       Date:  2019-04-16       Impact factor: 7.640

9.  Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study.

Authors:  Sharon J B Hanley; Hiromasa Fujita; Satomi Aoyama-Kikawa; Mitsunori Kasamo; Toshihiko Torigoe; Yoshihiro Matsuno; Sakuragi Noriaki
Journal:  J Gynecol Oncol       Date:  2021-11       Impact factor: 4.401

10.  National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.

Authors:  Megan A Smith; Maddison Sherrah; Farhana Sultana; Philip E Castle; Marc Arbyn; Dorota Gertig; Michael Caruana; C David Wrede; Marion Saville; Karen Canfell
Journal:  BMJ       Date:  2022-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.